deltatrials
Terminated PHASE2 INTERVENTIONAL 5-arm NCT04409873

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) (AMPoL)

Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19)

Sponsor: Rowpar Pharmaceuticals, Inc.

Updated 14 times since 2020 Last updated: Oct 26, 2023 Started: Mar 31, 2021 Primary completion: Sep 10, 2022 Completion: Sep 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The funder decided not to continue funding, causing enrollment to cease prematurely and curtailing originally planned analyses. Participants with any samples collected after the baseline pre-rinse samples were included in the analysis.

Listed as NCT04409873, this PHASE2 trial focuses on COVID-19 and Coronavirus Infections and remains terminated or withdrawn. Sponsored by Rowpar Pharmaceuticals, Inc., it has been updated 14 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshot~Jun 2022 – ~Oct 2022 · 4 months · monthly snapshot~Oct 2022 – ~Dec 2023 · 14 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: CompletedTerminated

  4. Oct 2022 — Dec 2023 [monthly]

    Completed PHASE2

    Status: RecruitingCompleted

  5. Jun 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

Show 9 earlier versions
  1. Nov 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  2. Jun 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  3. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  4. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE2

  5. Jan 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  7. Oct 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE2

  8. Aug 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE2

  9. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Rowpar Pharmaceuticals, Inc.
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations